Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
02 Novembro 2023 - 5:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health
& Services Forum, which takes place November 16th, 2023, at the
Westin New York Grand Central Hotel in New York City. John Aballi,
Exagen’s President and Chief Executive Officer and Kamal Adawi,
Exagen’s Chief Financial Officer, will present at 9:30 AM ET.
Interested parties may access the webcast of the presentation using
a link on Exagen’s website at https://investors.exagen.com/events.
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its
purpose as an organization is to provide clarity in autoimmune
disease decision making with the goal of improving patients’
clinical outcomes. Exagen is located in San Diego County,
California.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Exagen (NASDAQ:XGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024